AstraZeneca Looks To Challenge GSK’s Nucala With Fasenra EGPA Data
Head-To-Head Trial Of The Two IL-5 Inhibitors
AstraZeneca's Fasenra has demonstrated non-inferiority compared with GSK's fellow interleukin-5 inhibitor Nucala for eosinophilic granulomatosis with polyangiitis and the company hopes its more convenient single monthly subcutaneous injection will win market share if approved for the rare, immune-mediated inflammatory disease.
